Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis.

Tran TT, Yu H, Vidaillac C, Lim AYH, Abisheganaden JA, Chotirmall SH, Hadinoto K.

Int J Pharm. 2019 Mar 25;559:382-392. doi: 10.1016/j.ijpharm.2019.01.062. Epub 2019 Feb 4.

PMID:
30731256
2.

A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.

Tran TT, Vidaillac C, Yu H, Yong VFL, Roizman D, Chandrasekaran R, Lim AYH, Low TB, Tan GL, Abisheganaden JA, Koh MS, Teo J, Chotirmall SH, Hadinoto K.

Int J Pharm. 2018 Aug 25;547(1-2):368-376. doi: 10.1016/j.ijpharm.2018.06.017. Epub 2018 Jun 7.

PMID:
29886096
3.

Gender differences in bronchiectasis: a real issue?

Vidaillac C, Yong VFL, Jaggi TK, Soh MM, Chotirmall SH.

Breathe (Sheff). 2018 Jun;14(2):108-121. doi: 10.1183/20734735.000218. Review.

4.

In Vitro Evaluation of Biofilm Dispersal as a Therapeutic Strategy To Restore Antimicrobial Efficacy.

Roizman D, Vidaillac C, Givskov M, Yang L.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01088-17. doi: 10.1128/AAC.01088-17. Print 2017 Oct.

5.

In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm.

Tan JH, Vidaillac C, Yam JKH, Chua SL, Givskov M, Yang L.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02223-16. doi: 10.1128/AAC.02223-16. Print 2017 Jul.

6.

Unravelling of a mechanism of resistance to colistin in Klebsiella pneumoniae using atomic force microscopy.

Formosa C, Herold M, Vidaillac C, Duval RE, Dague E.

J Antimicrob Chemother. 2015 Aug;70(8):2261-70. doi: 10.1093/jac/dkv118. Epub 2015 May 27.

PMID:
26017037
8.

Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods.

Rybak MJ, Vidaillac C, Sader HS, Rhomberg PR, Salimnia H, Briski LE, Wanger A, Jones RN.

J Clin Microbiol. 2013 Jul;51(7):2077-81. doi: 10.1128/JCM.00448-13. Epub 2013 Apr 17.

9.

Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

Vidaillac C, Gardete S, Tewhey R, Sakoulas G, Kaatz GW, Rose WE, Tomasz A, Rybak MJ.

J Infect Dis. 2013 Jul;208(1):67-74. doi: 10.1093/infdis/jit127. Epub 2013 Mar 28.

10.

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ.

Antimicrob Agents Chemother. 2013 May;57(5):2376-9. doi: 10.1128/AAC.02354-12. Epub 2013 Feb 19.

11.

In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.

Vidaillac C, Benichou L, Duval RE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4856-61. doi: 10.1128/AAC.05996-11. Epub 2012 Jul 2.

12.

Macrolides and staphylococcal biofilms.

Parra-Ruiz J, Vidaillac C, Rybak MJ.

Rev Esp Quimioter. 2012 Mar;25(1):10-6. Review.

13.

Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents.

Dewal MB, Wani AS, Vidaillac C, Oupický D, Rybak MJ, Firestine SM.

Eur J Med Chem. 2012 May;51:145-53. doi: 10.1016/j.ejmech.2012.02.035. Epub 2012 Feb 25.

14.

Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ.

Antimicrob Agents Chemother. 2012 May;56(5):2691-5. doi: 10.1128/AAC.06185-11. Epub 2012 Feb 21.

15.

Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Rybak MJ.

Antimicrob Agents Chemother. 2012 Feb;56(2):955-9. doi: 10.1128/AAC.05849-11. Epub 2011 Nov 28.

16.

In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.

Vidaillac C, Parra-Ruiz J, Rybak MJ.

Diagn Microbiol Infect Dis. 2011 Dec;71(4):470-3. doi: 10.1016/j.diagmicrobio.2011.09.002. Epub 2011 Oct 21.

PMID:
22018937
17.

Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.

Patel D, Husain M, Vidaillac C, Steed ME, Rybak MJ, Seo SM, Kaatz GW.

Int J Antimicrob Agents. 2011 Nov;38(5):442-6. doi: 10.1016/j.ijantimicag.2011.06.010. Epub 2011 Aug 12.

PMID:
21840181
18.

Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus.

Hayakawa K, Marchaim D, Vidaillac C, Lephart P, Pogue JM, Sunkara B, Kotra H, Hasan A, Shango M, Yerramalla Y, Osunlana AM, Chopra T, Dhar S, Salimnia H, Rybak MJ, Kaye KS.

Infect Control Hosp Epidemiol. 2011 Sep;32(9):922-4. doi: 10.1086/661599. No abstract available.

PMID:
21828976
19.

Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.

Steed ME, Vidaillac C, Rose WE, Winterfield P, Kaatz GW, Rybak MJ.

Antimicrob Agents Chemother. 2011 Oct;55(10):4748-54. doi: 10.1128/AAC.00084-11. Epub 2011 Jul 25.

20.

In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.

Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ.

Int J Antimicrob Agents. 2011 Oct;38(4):301-6. doi: 10.1016/j.ijantimicag.2011.04.023. Epub 2011 Jul 20.

PMID:
21764263
21.
22.

Impact of dose de-escalation and escalation on daptomycin's pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model.

Vidaillac C, Steed ME, Rybak MJ.

Antimicrob Agents Chemother. 2011 May;55(5):2160-5. doi: 10.1128/AAC.01291-10. Epub 2011 Feb 14.

23.

A new assay to determine oritavancin concentrations.

Vidaillac C, Aeschlimann JR, Rybak MJ.

J Antibiot (Tokyo). 2010 Dec;63(12):717-9. doi: 10.1038/ja.2010.113. Epub 2010 Oct 13. No abstract available.

PMID:
20940724
24.

Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Steed ME, Vidaillac C, Rybak MJ.

Antimicrob Agents Chemother. 2010 Dec;54(12):5187-92. doi: 10.1128/AAC.00536-10. Epub 2010 Oct 4.

25.

Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.

Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ.

Antimicrob Agents Chemother. 2010 Oct;54(10):4329-34. doi: 10.1128/AAC.00455-10. Epub 2010 Aug 9.

26.

In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.

Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ.

Antimicrob Agents Chemother. 2010 Sep;54(9):3799-803. doi: 10.1128/AAC.00452-10. Epub 2010 Jun 28.

27.

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.

Vidaillac C, Leonard SN, Rybak MJ.

Int J Antimicrob Agents. 2010 Jun;35(6):527-30. doi: 10.1016/j.ijantimicag.2010.02.006. Epub 2010 Mar 26.

PMID:
20346632
28.

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Vidaillac C, Leonard SN, Rybak MJ.

Antimicrob Agents Chemother. 2009 Nov;53(11):4712-7. doi: 10.1128/AAC.00636-09. Epub 2009 Sep 8.

29.
30.

Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Vidaillac C, Rybak MJ.

Pharmacotherapy. 2009 May;29(5):511-25. doi: 10.1592/phco.29.5.511. Review.

PMID:
19397461
31.

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Vidaillac C, Leonard SN, Sader HS, Jones RN, Rybak MJ.

Antimicrob Agents Chemother. 2009 Jun;53(6):2360-6. doi: 10.1128/AAC.01452-08. Epub 2009 Apr 6.

32.

Synthesis of new 4-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]quinoxaline and 5-[2-(alkylamino) ethylthio]pyrrolo[1,2-a]thieno[3,2-e]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors.

Vidaillac C, Guillon J, Moreau S, Arpin C, Lagardère A, Larrouture S, Dallemagne P, Caignard DH, Quentin C, Jarry C.

J Enzyme Inhib Med Chem. 2007 Oct;22(5):620-31.

PMID:
18035830
33.

Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.

Vidaillac C, Guillon J, Arpin C, Forfar-Bares I, Ba BB, Grellet J, Moreau S, Caignard DH, Jarry C, Quentin C.

Antimicrob Agents Chemother. 2007 Mar;51(3):831-8. Epub 2006 Nov 13.

35.

Synthesis and initial results for MAO-B inhibition by new N-propargyl-3-pyrrol-1-ylindanamine derivatives, analogues of rasagiline.

Guillon J, Hébert G, Dallemagne P, Léger JM, Vidaillac C, Thé C, Lisowski V, Rault S, Demotes-Mainard J, Jarry C.

J Enzyme Inhib Med Chem. 2003 Apr;18(2):147-53.

PMID:
12943198

Supplemental Content

Loading ...
Support Center